Zhen Xu

CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors

Zhen Xu, Cassandra J Vandenberg, Elizabeth Lieschke, Ladina Di Rago, Clare L Scott, Ian J Majewski

Journal article  |  2021  |  MOLECULAR CANCER RESEARCH

Patients with cancer treated with PARP inhibitors (PARPi) experience various side effects, with hematologic toxicity being most co..

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Rachel Thijssen, Sarah T Diepstraten, Donia Moujalled, Edward Chew, Christoffer Flensburg, Melissa X Shi, Michael A Dengler, Veronique Litalien, Sarah MacRaild, Maoshan Chen, Natasha S Anstee, Boris Reljic, Sarah S Gabriel, Tirta M Djajawi, Chris D Riffkin, Brandon J Aubrey, Catherine Chang, Lin Tai, Zhen Xu, Thomas Morley, et al.

Journal article  |  2021  |  BLOOD

Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative treatment for patients with various leukemi..

Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma

Piers Blombery, Richard W Birkinshaw, Tamia Nguyen, Jia-nan Gong, Ella R Thompson, Zhen Xu, David A Westerman, Peter E Czabotar, Michael Dickinson, David CS Huang, John F Seymour, Andrew W Roberts

Journal article  |  2019  |  BRITISH JOURNAL OF HAEMATOLOGY

Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice

Natasha S Anstee, Rebecca A Bilardi, Ashley P Ng, Zhen Xu, Mikara Robati, Cassandra J Vandenberg, Suzanne Cory

Journal article  |  2019  |  CELL DEATH AND DIFFERENTIATION

Many acute myeloid leukaemias (AMLs) express high levels of BCL-2 and MCL-1, especially after therapy. To test the impact of these..

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Piers Blombery, Mary Ann Anderson, Jia-nan Gong, Rachel Thijssen, Richard W Birkinshaw, Ella R Thompson, Charis E Teh, Tamia Nguyen, Zhen Xu, Christoffer Flensburg, Thomas E Lew, Ian J Majewski, Daniel HD Gray, David A Westerman, Constantine S Tam, John F Seymour, Peter E Czabotar, David CS Huang, Andrew W Roberts

Journal article  |  2019  |  CANCER DISCOVERY

The BCL2 inhibitor venetoclax induces high rates of durable remission in patients with previously treated chronic lymphocytic leuk..

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Piers Blombery, Mary Ann Anderson, Jianan Gong, Rachel Thijssen, Richard W Birkinshaw, Ella Thompson, Charis E Teh, Tamia Nguyen, Zhen Xu, Christoffer Flensburg, Thomas Lew, Ian Majewski, Daniel Gray, David Alan Westerman, Constantine S Tam, John F Seymour, Peter E Czabotar, David Huang, Andrew W Roberts

Conference Proceedings  |  2018  |  BLOOD

Abstract Venetoclax induces high rates of response (~80%), including complete remissions (CR) in patients with heav..

Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors

Phillip P Sharp, Jean-Marc Garnier, Tamas Hatfaludi, Zhen Xu, David Segal, Kate E Jarman, Helene Jousset, Alexandra Garnham, John T Feutrill, Anthony Cuzzupe, Peter Hall, Scott Taylor, Carl R Walkley, Dean Tyler, Mark A Dawson, Peter Czabotar, Andrew F Wilks, Stefan Glaser, David CS Huang, Christopher J Burns

Journal article  |  2017  |  ACS MEDICINAL CHEMISTRY LETTERS

A number of diazepines are known to inhibit bromo- and extra-terminal domain (BET) proteins. Their BET inhibitory activity derives..

Plasmacytoid dendritic cells are short-lived: reappraising the influence of migration, genetic factors and activation on estimation of lifespan

Yifan Zhan, Kevin V Chow, Priscilla Soo, Zhen Xu, Jamie L Brady, Kate E Lawlor, Seth L Masters, Meredith O'keeffe, Ken Shortman, Jian-Guo Zhang, Andrew M Lew

Journal article  |  2016  |  SCIENTIFIC REPORTS

Plasmacytoid dendritic cells (pDCs) play an important role in immunity to certain pathogens and immunopathology in some autoimmune..